Hickey Martha, Higham Jenny M, Fraser Ian
The University ofMelbourne, The RoyalWomen’sHospital,Melbourne, Australia.
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD001895. doi: 10.1002/14651858.CD001895.pub3.
Irregular menstrual bleeding may arise due to exogenous sex steroids, lesions of the genital tract or be associated with anovulation. Irregular bleeding due to oligo/anovulation (previously called dysfunctional uterine bleeding or DUB) is more common at the extremes of reproductive life, and in women with ovulatory disorders such as polycystic ovary syndrome (PCOS). In anovulatory cycles there may be prolonged oestrogen stimulation of the endometrium without progesterone withdrawal and so cycles are irregular and bleeding may be heavy. This is the rationale for using cyclical progestogens during the second half of the menstrual cycle, in order to provoke a regular withdrawal bleed. Continuous progestogen is intended to induce endometrial atrophy and hence to prevent oestrogen-stimulated endometrial proliferation. Progestogens, and oestrogens and progestogens in combination, are widely used in the management of irregular menstrual bleeding, but the regime, dose and type of progestogen used vary widely, with little consensus about the optimum treatment approach.
To determine the effectiveness and acceptability of progestogens alone or in combination with oestrogens in the regulation of irregular menstrual bleeding associated with oligo/anovulation.
We searched the following databases in February 2012: Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and reference lists of articles.
All randomised controlled trials of progestogens (via any route) alone or in combination with oestrogens in the treatment of irregular menstrual bleeding associated with oligo/anovulation.
Study quality assessment and data extraction were carried out independently by two review authors. All authors were experts in the content of this review.
No randomised trials were identified that compared progestogens with oestrogens and progestogens or with placebo in the management of irregular bleeding associated with oligo/anovulation.
AUTHORS' CONCLUSIONS: There is a paucity of randomised studies relating to the use of progestogens and of oestrogens and progestogens in combination in the treatment of irregular menstrual bleeding associated with anovulation. There is no consensus about which regimens are most effective. Further research is needed to establish the role of these hormonal treatments in the management of this common gynaecological problem.
月经不规则出血可能由外源性性激素、生殖道病变引起,或与无排卵有关。因稀发/无排卵导致的不规则出血(以前称为功能失调性子宫出血或功血)在生殖年龄两端以及患有排卵障碍(如多囊卵巢综合征,PCOS)的女性中更为常见。在无排卵周期中,子宫内膜可能受到雌激素的持续刺激而无孕激素撤退,因此月经周期不规则,出血可能较多。这就是在月经周期后半期使用周期性孕激素以引发规律撤退性出血的理论依据。持续使用孕激素旨在诱导子宫内膜萎缩,从而防止雌激素刺激的子宫内膜增生。孕激素以及雌激素和孕激素联合使用,在月经不规则出血的管理中被广泛应用,但所使用的孕激素方案、剂量和类型差异很大,对于最佳治疗方法几乎没有共识。
确定单独使用孕激素或与雌激素联合使用在调节与稀发/无排卵相关的月经不规则出血方面的有效性和可接受性。
我们于2012年2月检索了以下数据库:Cochrane月经失调与生育力低下小组试验注册库、Cochrane对照试验中央注册库(CENTRAL)、MEDLINE、EMBASE、PsycINFO以及文章的参考文献列表。
所有关于单独使用孕激素(通过任何途径)或与雌激素联合使用治疗与稀发/无排卵相关的月经不规则出血的随机对照试验。
由两位综述作者独立进行研究质量评估和数据提取。所有作者均为本综述内容方面的专家。
未发现有随机试验比较孕激素与雌激素及孕激素联合使用或与安慰剂在治疗与稀发/无排卵相关的不规则出血方面的效果。
关于使用孕激素以及雌激素和孕激素联合使用治疗与无排卵相关的月经不规则出血的随机研究很少。对于哪种方案最有效尚无共识。需要进一步研究以确定这些激素治疗在管理这一常见妇科问题中的作用。